Mucinase from Bacteroidesthetaiotaomicron as mucolytic for mucinous cancer pseudomyxoma peritonei
Frontiers in Microbiology · 01.05.2026 · 17
DOI: 10.3389/fmicb.2026.1722421 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 01.05.2026. Verfasst von Jun Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Interdisciplinary Research Group on Microscopic Imaging and Drug Development, Shenzhen Bay Laboratory, Shenzhen, China. Die Arbeit nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Mucinous cancers are characterized by tumor gland cells secreting copious amounts of mucus that forms gel-like structures. Pseudomyxoma peritonei (PMP), a rare yet prototypical mucinous malignancy, exemplifies this pathology. Biologically inert mucus coats tumor cells, promoting colonization, immune evasion, and chemoresistance. Pathological mucus accumulation leads to intra-abdominal hypertension, refractory abdominal pain, abdominal adhesions, and intestinal obstruction because of the lack of rapid, efficient, and safe clinical strategies for mucin clearance. Current management relies on extensive cytoreductive surgery to excise tumor masses and adherent mucus. Here, we present an integrated workflow spanning intestinal probiotic protease discovery for the development of mucolytic therapy. By cultivating Bacteroides thetaiotaomicron ( B. theta ) with PMP-derived mucus as the sole nutrient source, we identified its intrinsic mucolytic capacity. Crucially, transcriptomic analysis revealed that B. theta orchestrates mucus degradation via the PULs gene cluster, with concomitant upregulation of the M60 family metalloproteinases BT4244, BT3015, and BT4272. Functional validation classified these enzymes as “mucinases” responsible for tumor-associated mucin cleavage and mucolysis. Our study provides a foundation for enzyme-targeted PMP therapy, offering a paradigm shift toward minimally invasive, high-efficacy mucolysis. Our findings highlight the translational potential of microbial proteases in addressing clinical challenges posed by mucinous malignancies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Interdisciplinary Research Group on Microscopic Imaging and Drug Development, Shenzhen Bay Laboratory, Shenzhen, China.
- Institute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen, China.
- School of Food Science and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, China.
- College of Life Science, Northwest A&F University, Xianyang, China.
- School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, China.
Zitieren
APA
Liu, J., Zhan, L., Xu, C., Wei, R., Bai, C., Guan, M., & Sun, Z. (2026). Mucinase from Bacteroidesthetaiotaomicron as mucolytic for mucinous cancer pseudomyxoma peritonei. Frontiers in Microbiology, 17. https://doi.org/10.3389/fmicb.2026.1722421
Vancouver
Liu J, Zhan L, Xu C, Wei R, Bai C, Guan M, et al. Mucinase from Bacteroidesthetaiotaomicron as mucolytic for mucinous cancer pseudomyxoma peritonei. Frontiers in Microbiology. 2026;17. doi:10.3389/fmicb.2026.1722421
BibTeX
@article{Liu2026,
author = {Liu, Jun and Zhan, Lingpeng and Xu, Chengjing and Wei, Runling and Bai, Chengyu and Guan, Miao and Sun, Zhenglong},
title = {Mucinase from Bacteroidesthetaiotaomicron as mucolytic for mucinous cancer pseudomyxoma peritonei},
journal = {Frontiers in Microbiology},
year = {2026},
volume = {17},
doi = {10.3389/fmicb.2026.1722421}
}
EUVIMED